PMN$3.43+14.33%
ProMIS Neurosciences Inc.
Sector: Pharmaceutical PreparationsIndustry: BiotechnologyCountry: CAExchange: Nasdaq
Mkt Cap:$30.76M
Float & O/S:
Inst Own:
DilutionScan read 26 of ProMIS Neurosciences Inc.'s SEC filings and found 13 warrant series, 2 ATM programs, 7 shelf registrations and 4 completed offerings on file for PMN. The latest dilution event on file is ATM sales on Jun 30, 2026. Analysis updated Oct 4, 2026.
Signal8 Summary
PMN
Clinical-stage biotech, high dilution risk
- Business
- WeakNo revenue, $39.7M net loss, 10-month modeled runway
- Stock risk
- High$30M micro-cap, 1-for-25 reverse split, shares +66% YoY, 295% dilution overhang
Snapshot
ProMIS is a clinical-stage biotech with no product revenue, developing an Alzheimer's antibody (PMN310) now in a Phase 1b trial. FY 2025 net loss was $39.7M and operating cash flow was -$28.1M.
What's Happening Right Now
- : On Oct 6, 2026, ProMIS appointed Ivana Rubino, Ph.D. as Chief Commercial Officer to lead launch-readiness for PMN310 ahead of the 12-month PRECISE-AD data expected in Q1 2027; she received an inducement option for 80,000 shares at $9.37.
- : On Aug 13, 2026, ProMIS reported Q2 2026 results with a $11.7M net loss, $53.4M cash and short-term investments after a $70.1M January private placement, and positive blinded 6-month interim PRECISE-AD data for PMN310 showing zero ARIA-E cases across 136 participants.
- : ProMIS's Q2 2026 10-Q (filed Aug 13, 2026) showed a $20.0M first-half net loss, an accumulated deficit of $150.4M, operating cash burn more than doubling to $22.8M from $8.8M a year earlier, 8.97M shares outstanding, and 9.34 million warrants outstanding creating a sizable dilution overhang.
- : Registered $200.00M of securities for sale on Form S-3.
- : Registered 13.83M shares for sale on Form S-3.
- : Raised $75.50M in gross proceeds through a private placement (PIPE), with warrants over 7.02M shares.
